Insmed Inc (INSM)vsMadrigal Pharmaceuticals Inc (MDGL)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
MDGL
Madrigal Pharmaceuticals Inc
$461.93
+3.80%
HEALTHCARE · Cap: $10.21B
Smart Verdict
WallStSmart Research — data-driven comparison
Madrigal Pharmaceuticals Inc generates 58% more annual revenue ($958.40M vs $606.42M). INSM leads profitability with a -2.1% profit margin vs -30.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
MDGL
Avoid31
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
No standout strengths identified
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
Trading at 17.5x book value
2.1% revenue growth
0.0% earnings growth
ROE of -42.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : MDGL
MDGL has a balanced fundamental profile.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : MDGL
The primary concerns for MDGL are Price/Book, Revenue Growth, EPS Growth.
Key Dynamics to Monitor
INSM carries more volatility with a beta of 1.17 — expect wider price swings.
MDGL is growing revenue faster at 2.1% — sustainability is the question.
MDGL generates stronger free cash flow (-134M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
INSM scores higher overall (39/100 vs 31/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Madrigal Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic and liver diseases. The company is headquartered in West Conshohocken, Pennsylvania.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?